Solifenacin Succinate Market Report 2025 (Global Edition)

Global Solifenacin Succinate Market Report 2024 Market Size Split by Type (Above 99%, Below 99%), by Application (Tablet, Capsule, Others)

Solifenacin Succinate Market Report Description

We have various report editions of Solifenacin Succinate Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Solifenacin Succinate Market Insights Video

Competitive Landscape of the Solifenacin Succinate Market

In the Solifenacin Succinate market's competitive landscape, numerous key competitors are driving innovation and growth. The Solifenacin Succinate market is characterized by the presence of several global pharmaceutical companies that are involved in the manufacturing, research, and distribution of treatments for overactive bladder (OAB). The competitive landscape is shaped by product innovation, regulatory approvals, market penetration strategies, and partnerships among key players.

Top Companies Market Share in Solifenacin Succinate Industry: (In no particular order of Rank)

• Astellas Pharma
• Teva
• Ajanta Pharma
• Aurobindo Pharma
• Glenmark Pharmaceuticals
• Qilu Pharmaceutical
• Cipla
• Jiangxi Boya Seehot Pharmaceutical
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Solifenacin Succinate Market

Which Region Dominates the Solifenacin Succinate Market in 2024?

According to Cognitive Market Research, North America currently dominates the Solifenacin Succinates market, and the region is expected to have significant growth during the projected period. One of the key drivers of the Solifenacin Succinate market in North America is the rising prevalence of overactive bladder (OAB), especially among the aging population. OAB is a widespread condition in the region, and its incidence continues to grow. According to the Urology Care Foundation, millions of individuals in the U.S. suffer from OAB, with the numbers climbing as the population ages. A recent study published in Scientific Reports by researchers in China analyzed OAB trends among U.S. adult men between 2005 and 2020. The study found that the overall prevalence of OAB in this group increased from 11.3% in 2005–2008 to 14.5% in 2015–2020, with significant links to factors such as age, race, obesity, diabetes, and other chronic conditions. Given that OAB is more prevalent in older adults, the growing elderly population is driving demand for treatments like Solifenacin Succinate.

Which Region is Expanding at the Fastest CAGR?

Asia-Pacific is expected to make significant gains during the projected period, with the greatest compound annual growth rate (CAGR). Chronic conditions like obesity and diabetes, both significant risk factors for overactive bladder (OAB), are increasing across the Asia Pacific region. As these conditions become more prevalent, so does the occurrence of urinary disorders, fueling the demand for treatments such as Solifenacin Succinate. The International Diabetes Federation reports that the Asia Pacific region has the largest number of people with diabetes, a condition closely linked to bladder dysfunction and OAB. According to the 2023 ICMR INDIAB study, India alone has 101 million diabetes cases. India is among the seven countries in the IDF South-East Asia (SEA) region, where 90 million individuals currently live with diabetes. This number is expected to surge to 151.5 million by 2045, highlighting how the rising incidence of obesity and diabetes is driving the demand for OAB therapies in the region.

The current report Scope analyzes Solifenacin Succinate Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Solifenacin Succinate Market

According to Cognitive Market Research, the global Solifenacin Succinate market size was estimated at USD 102151.2 Million, out of which North America held the major market share of more than 40% of the global revenue with a market size of USD 40860.4 million in 2024 and will grow at a compound annual growth rate (CAGR) of 49.1% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the Solifenacin Succinate market with a market size of USD 32238.9 million in 2024 and is projected to grow at a CAGR of 48.9% during the forecast period. The U.S. rising number of individuals seeking effective treatment for urinary disorders, driving the market.
• The Canada Solifenacin Succinate market had a market share of USD 4903.2 million in 2024 and is projected to grow at a CAGR of 49.9% during the forecast period. In Canada, the demand for the Solifenacin Succinate market is driven by growing elderly population experiencing OAB symptoms and a heightened awareness of available treatment options for managing urinary conditions.
• The Mexico Solifenacin Succinate market is projected to witness growth at a CAGR of 49.6% during the forecast period, with a market size of USD 3718.3 million in 2024.

Europe Solifenacin Succinate Market

According to Cognitive Market Research, the global Solifenacin Succinate market size was estimated at USD 102151.2 Million, out of which Europe held the market share of more than 30% of the global revenue with a market size of USD 30645.3 million in 2024 and will grow at a compound annual growth rate (CAGR) of 49.4% from 2024 to 2031.

• The United Kingdom Solifenacin Succinate market had a market share of USD 5148.4 million in 2024 and is projected to grow at a CAGR of 50.2% during the forecast period. In the UK, Solifenacin Succinate sales witness an upswing due to the increasing prevalence of overactive bladder (OAB) among the aging population.
• The France Solifenacin Succinate market is projected to witness growth at a CAGR of 48.6% during the forecast period, with a market size of USD 2819.3 million in 2024.
• According to Cognitive Market Research, the German Solifenacin Succinate market size was valued at USD 6067.7 million in 2024 and is projected to grow at a CAGR of 49.6% during the forecast period. In Germany, Solifenacin Succinate surged due to the growing awareness of urinary disorders, and a strong healthcare infrastructure.
• The Italy Solifenacin Succinate market is projected to witness growth at a CAGR of 48.8% during the forecast period, with a market size of USD 2635.50 million in 2024.
• The Russia Solifenacin Succinate market is projected to witness growth at a CAGR of 48.4% during the forecast period, with a market size of USD 4750.0 million in 2024.
• The Spain Solifenacin Succinate market is projected to witness growth at a CAGR of 48.5% during the forecast period with a market size of USD 2512.9 million in 2024
• The Luxembourg Solifenacin Succinate market is projected to witness growth at a CAGR of 49.5% during the forecast period, with a market size of USD 950.0 million in 2024.
• The Portugal Solifenacin Succinate market is projected to witness growth at a CAGR of 49.2% during the forecast period, with a market size of USD 643.5 million in 2024.
• The Greece Solifenacin Succinate market is projected to witness growth at a CAGR of 49.7% during the forecast period, with a market size of USD 367.7 million in 2024.
• The Rest of Europe's Solifenacin Succinate market is projected to witness growth at a CAGR of 48.1% during the forecast period, with a market size of USD 4750.0 million in 2024.

Asia Pacific Solifenacin Succinate Market

According to Cognitive Market Research, the global Solifenacin Succinate market size was estimated at USD 102151.2 Million, out of which Asia Pacific held the market share of around 23% of the global revenue with a market size of USD 23494.7 million in 2024 and will grow at a compound annual growth rate (CAGR) of 52.9% from 2024 to 2031.

• According to Cognitive Market Research, the China Solifenacin Succinate market size was valued at USD 10572.6 million in 2024 and is projected to grow at a CAGR of 52.4% during the forecast period. In China, the demand for the Solifenacin Succinate market is driven by the growing prevalence of overactive bladder (OAB) and related urinary disorders due to increasing rates of chronic conditions like diabetes and obesity.
• The Japan Solifenacin Succinate market is projected to witness growth at a CAGR of 51.4% during the forecast period, with a market size of USD 3242.2 million in 2024.
• The India Solifenacin Succinate market had a market share of USD 2819.3 million in 2024 and is projected to grow at a CAGR of 54.7% during the forecast period. India's expanding pharmaceutical industry and rapidly expanding healthcare sector, driving the market.
• The South Korean Solifenacin Succinate market is projected to witness growth at a CAGR of 52.0% during the forecast period, with a market size of USD 2349.4 million in 2024.
• The Australian Solifenacin Succinate market is projected to witness growth at a CAGR of 52.6% during the forecast period, with a market size of USD 1221.7 million in 2024.
• The South East Asia Solifenacin Succinate market is projected to witness growth at a CAGR of 53.9% during the forecast period, with a market size of USD 1621.1 million in 2024.
• The Rest of Asia Pacific Solifenacin Succinate market is projected to witness growth at a CAGR of 52.7% during the forecast period, with a market size of USD 1668.1 million in 2024.

South America Solifenacin Succinate Market

According to Cognitive Market Research, the global Solifenacin Succinate market size was estimated at USD 102151.2 Million, out of which Latin America held the market share of around 5% of the global revenue with a market size of USD 5107.5 million in 2024 and will grow at a compound annual growth rate (CAGR) of 50.3% from 2024 to 2031.

• According to Cognitive Market Research, the Brazil Solifenacin Succinate market size was valued at USD 2186.0 million in 2024 and is projected to grow at a CAGR of 50.9% during the forecast period. Solifenacin Succinate flourished in Brazil due to a significant rise in the number of patients with chronic health conditions such as diabetes and obesity, which are known to exacerbate overactive bladder (OAB) symptoms.
• Argentina's Solifenacin Succinate market had a market share of USD 858.0 million in 2024 and is projected to grow at a CAGR of 51.2% during the forecast period. In Argentina, the demand for the Solifenacin Succinate market is driven by the country's efforts to improve healthcare accessibility and the increasing recognition and treatment of urinary disorders, supported by both public health initiatives and advancements in medical care.
• Colombia Solifenacin Succinate market is projected to witness growth at a CAGR of 50.1% during the forecast period, with a market size of USD 454.5 million in 2024.
• Peru Solifenacin Succinate market is projected to witness growth at a CAGR of 50.5% during the forecast period, with a market size of USD 418.8 million in 2024.
• Chile's Solifenacin Succinate market is projected to witness growth at a CAGR of 50.6% during the forecast period, with a market size of USD 367.7 million in 2024.
• The Rest of Latin America's Solifenacin Succinate market is projected to witness growth at a CAGR of 49.4% during the forecast period, with a market size of USD 822.3 million in 2024.

Middle East and Africa Solifenacin Succinate Market

According to Cognitive Market Research, the global Solifenacin Succinate market size was estimated at USD 102151.2 Million, out of which the Middle East and Africa held the major market share of around 2% of the global revenue with a market size of USD 2043.0 million in 2024 and will grow at a compound annual growth rate (CAGR) of 50.6% from 2024 to 2031.

• The GCC Countries Solifenacin Succinate market is projected to witness growth at a CAGR of 51.4% during the forecast period, with a market size of USD 874.4 million in 2024. Solifenacin Succinate sales flourish due to rapid urbanization and lifestyle changes, which contribute to higher rates of conditions like obesity and diabetes.
• The Egypt Solifenacin Succinate market is projected to witness growth at a CAGR of 50.9% during the forecast period, with a market size of USD 214.5 million in 2024.
• The South African Solifenacin Succinate market is projected to witness growth at a CAGR of 51.6% during the forecast period, with a market size of USD 322.8 million in 2024. Solifenacin Succinate sales flourished in South Africa due to the growing middle class with improved access to healthcare services and medications.
• The Turkey Solifenacin Succinate market is projected to witness growth at a CAGR of 50.1% during the forecast period, with a market size of USD 175.7 million in 2024.
• The Nigeria Solifenacin Succinate market is projected to witness growth at a CAGR of 49.7% during the forecast period, with a market size of USD 214.5 million in 2024.
• The Rest of the MEA Solifenacin Succinate market is projected to witness growth at a CAGR of 49.6% during the forecast period, with a market size of USD 241.0 million in 2024.

Solifenacin Succinate Market Analysis

Solifenacin Succinate Market Type Segment Analysis

According to Cognitive Market Research, Above 99% are likely to dominate the Solifenacin Succinate Market over the forecast period. Purity levels exceeding 99% are critical in pharmaceutical applications, as they minimize the presence of impurities and reduce the likelihood of side effects or adverse reactions. Regulatory agencies such as the FDA and EMA emphasize stringent quality standards, making high-purity Solifenacin Succinate more desirable for drug manufacturers and healthcare providers. Additionally, high-purity Solifenacin Succinate offers improved bioavailability and stability, which enhances the effectiveness of the medication in treating overactive bladder (OAB). With growing awareness among healthcare professionals and patients regarding the quality and safety of medications, pharmaceutical companies are increasingly opting for higher-purity versions to meet these expectations.

Below 99% is the fastest-growing segment in the Solifenacin Succinate Market. Solifenacin Succinate with slightly lower purity levels still meets basic regulatory standards for safety and efficacy, making it a more affordable option for both pharmaceutical companies and patients. The lower cost associated with the "below 99%" purity type allows pharmaceutical companies to offer competitive pricing, making the medication more accessible to a larger population. This is crucial in regions where healthcare infrastructure is still developing and where there is a greater reliance on generic and affordable drugs..

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Solifenacin Succinate Industry. Request a Free Sample PDF!

Solifenacin Succinate Market Application Segment Analysis

According to Cognitive Market Research, the Tablet segment holds the largest share of the market. Tablets are the most common and preferred form of medication delivery due to their ease of administration. Solifenacin Succinate tablets are simple to consume and allow for precise dosing, which enhances patient compliance, particularly among older adults who often suffer from overactive bladder (OAB). As OAB is more prevalent in elderly populations, the convenience of taking a single daily tablet boosts adherence to the treatment plan, driving demand in this segment.

In the Solifenacin Succinate Market, the Capsule segment has been expanding at a rapid pace. Capsules are often preferred by patients, particularly those who find tablets difficult to swallow. The smooth, gelatin-based coating of capsules makes them easier to ingest, especially for older adults who commonly suffer from overactive bladder (OAB). This preference for capsules enhances patient compliance, leading to an increased demand in the market.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Author's Conclusion